PE20081377A1 - Compuestos de tiazol pirazolopirimidina - Google Patents

Compuestos de tiazol pirazolopirimidina

Info

Publication number
PE20081377A1
PE20081377A1 PE2007001271A PE2007001271A PE20081377A1 PE 20081377 A1 PE20081377 A1 PE 20081377A1 PE 2007001271 A PE2007001271 A PE 2007001271A PE 2007001271 A PE2007001271 A PE 2007001271A PE 20081377 A1 PE20081377 A1 PE 20081377A1
Authority
PE
Peru
Prior art keywords
thiazol
propyl
ethyl
compounds
disorders
Prior art date
Application number
PE2007001271A
Other languages
English (en)
Spanish (es)
Inventor
Zhaogen Chen
Erik James Hembre
Philip Arthur Hipskind
Takako Takakuwa
James Lee Toth
Hamdouchi Chafiq Hamdouchi
Jason Kenneth Myers
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081377(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20081377A1 publication Critical patent/PE20081377A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2007001271A 2006-09-20 2007-09-20 Compuestos de tiazol pirazolopirimidina PE20081377A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82626406P 2006-09-20 2006-09-20

Publications (1)

Publication Number Publication Date
PE20081377A1 true PE20081377A1 (es) 2008-09-18

Family

ID=38924802

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001271A PE20081377A1 (es) 2006-09-20 2007-09-20 Compuestos de tiazol pirazolopirimidina

Country Status (33)

Country Link
US (1) US8030304B2 (enExample)
EP (1) EP2094709B1 (enExample)
JP (1) JP5161226B2 (enExample)
KR (1) KR101088239B1 (enExample)
CN (1) CN101516887B (enExample)
AR (1) AR062886A1 (enExample)
AT (1) ATE481405T1 (enExample)
AU (1) AU2007297421B2 (enExample)
BR (1) BRPI0717023B8 (enExample)
CA (1) CA2663511C (enExample)
CL (1) CL2007002693A1 (enExample)
CR (1) CR10682A (enExample)
CY (1) CY1110854T1 (enExample)
DE (1) DE602007009305D1 (enExample)
DK (1) DK2094709T3 (enExample)
EA (1) EA015179B1 (enExample)
ES (1) ES2350282T3 (enExample)
HR (1) HRP20100516T1 (enExample)
IL (1) IL197614A (enExample)
MA (1) MA30798B1 (enExample)
MX (1) MX2009003125A (enExample)
MY (1) MY146388A (enExample)
NO (1) NO20091489L (enExample)
NZ (1) NZ575572A (enExample)
PE (1) PE20081377A1 (enExample)
PL (1) PL2094709T3 (enExample)
PT (1) PT2094709E (enExample)
RS (1) RS51545B (enExample)
SI (1) SI2094709T1 (enExample)
TN (1) TN2009000095A1 (enExample)
TW (1) TWI402269B (enExample)
UA (1) UA96458C2 (enExample)
WO (1) WO2008036579A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2739422C (en) * 2008-10-02 2013-03-12 Eli Lilly And Company Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PT3096756T (pt) * 2014-01-21 2024-08-26 Neurocrine Biosciences Inc Antagonistas do recetor crf1 para o tratamento da hiperplasia adrenal congénita
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
CA3039026A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
AU2018318990B2 (en) * 2017-08-14 2023-01-05 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
BR112020002967A2 (pt) * 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
WO2019210266A1 (en) * 2018-04-27 2019-10-31 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
CN109134481B (zh) * 2018-08-07 2021-05-14 中山大学 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
MA54395A (fr) 2018-12-07 2022-03-16 Neurocrine Biosciences Inc Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
EP3986416A4 (en) * 2019-07-19 2023-06-28 Spruce Biosciences, Inc. Methods of treating congenital adrenal hyperplasia
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
EP4069697B1 (en) * 2019-12-04 2025-07-16 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
GR1010096B (el) * 2020-07-02 2021-10-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
WO2022036123A1 (en) 2020-08-12 2022-02-17 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
US20240024330A1 (en) 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
EP4308553A4 (en) 2021-03-19 2025-01-22 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
KR20240109274A (ko) * 2021-11-19 2024-07-10 스프루스 바이오사이언시스 인코포레이티드 틸다서폰트의 결정질 조성물 및 이의 사용 및 제조 방법
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023163945A1 (en) * 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
WO2025188842A1 (en) * 2024-03-08 2025-09-12 Spruce Biosciences, Inc. Amorphous solid dispersion of tildacerfont formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0173172B1 (ko) 1992-12-17 1999-02-01 알렌 제이. 스피겔 Crf 길항제로서의 피롤로피리미딘
IL123835A0 (en) * 1996-02-07 1998-10-30 Janssen Pharmaceutica Nv Pyrazolopyrimidines as CRF receptor antagonists
DK0915880T3 (da) 1996-07-24 2008-02-11 Bristol Myers Squibb Pharma Co Azolotriaziner og pyrimidiner
CZ299451B6 (cs) * 1996-07-24 2008-07-30 Bristol-Myers Squibb Pharma Company [1,5-a]-Pyrazolo-1,3,5- triaziny jejich použití afarmaceutické kompozice na jejich bázi
WO1998008847A1 (en) 1996-08-28 1998-03-05 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
CZ20021089A3 (cs) 1999-09-30 2002-11-13 Neurogen Corporation Aminosustituované pyrazolo[1,5-a]-1,5-pyrimidiny a pyrazolo[1,5-a]-1,3,5-triaziny
RS50863B (sr) 2001-03-13 2010-08-31 Bristol-Myers Squibb Pharma Company 4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoksipirid-3-il) pirazolo/1,5a/-1,3,5-triazin,njegovi enantiomeri i farmaceutski prihvatljive soli kao ligandi receptora za faktor koji oslobađa kortikotropin
RU2394035C2 (ru) * 2003-12-22 2010-07-10 Эс Би ФАРМКО ПУЭРТО РИКО ИНК. Антагонисты crf-рецепторов и способы, относящиеся к ним

Also Published As

Publication number Publication date
NO20091489L (no) 2009-04-16
MY146388A (en) 2012-08-15
MX2009003125A (es) 2009-05-28
BRPI0717023B1 (pt) 2019-11-19
KR20090052366A (ko) 2009-05-25
CL2007002693A1 (es) 2008-04-18
US8030304B2 (en) 2011-10-04
IL197614A (en) 2012-10-31
DK2094709T3 (da) 2010-12-06
CY1110854T1 (el) 2015-06-10
JP2010504344A (ja) 2010-02-12
AU2007297421A1 (en) 2008-03-27
ES2350282T3 (es) 2011-01-20
US20100222339A1 (en) 2010-09-02
PT2094709E (pt) 2010-10-04
EA200970303A1 (ru) 2009-10-30
TN2009000095A1 (en) 2010-08-19
AU2007297421B2 (en) 2012-03-08
DE602007009305D1 (de) 2010-10-28
HK1132505A1 (en) 2010-02-26
CN101516887A (zh) 2009-08-26
PL2094709T3 (pl) 2011-02-28
NZ575572A (en) 2011-10-28
EP2094709B1 (en) 2010-09-15
UA96458C2 (ru) 2011-11-10
AR062886A1 (es) 2008-12-10
CA2663511A1 (en) 2008-03-27
RS51545B (sr) 2011-06-30
SI2094709T1 (sl) 2011-01-31
ATE481405T1 (de) 2010-10-15
KR101088239B1 (ko) 2011-11-30
TWI402269B (zh) 2013-07-21
CR10682A (es) 2009-08-13
JP5161226B2 (ja) 2013-03-13
BRPI0717023B8 (pt) 2021-05-25
WO2008036579A1 (en) 2008-03-27
BRPI0717023A2 (pt) 2014-03-11
EA015179B1 (ru) 2011-06-30
MA30798B1 (fr) 2009-10-01
TW200821312A (en) 2008-05-16
IL197614A0 (en) 2009-12-24
CN101516887B (zh) 2011-11-02
CA2663511C (en) 2012-12-04
HRP20100516T1 (hr) 2010-10-31
EP2094709A1 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
PE20081377A1 (es) Compuestos de tiazol pirazolopirimidina
ATE424402T1 (de) Imidazopyridinverbindungen
ES2299896T3 (es) Derivados de benzazepina como antagonistas h3 de histamina.
EA200801000A1 (ru) Производные пиразоло[1,5-альфа]пиримидила, полезные в качестве антагонистов рецептора рилизинг-фактора кортикотропина (crf)
IL210071A (en) Derivatives of {3– (pyrid – 2 – illmethyl) –3 h– [1, 2, 3] triazolo [4, 5 – d] pyrimidine-5-amine}, their pharmaceutical preparations and their use in drug preparation
MX2009003098A (es) Compuestos de tiofen pirazolopirimidina.
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
PE20081159A1 (es) Inhibidores de las quinasas y metodos para su utilizacion
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
PE20070093A1 (es) Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
EA200800992A1 (ru) 2-амино-7,8-дигидро-6н-пиридо[4,3-d]пиримидин-5-оны, способ их получения, способ терапии с их помощью, компонент композиции и композиция на их основе, 2,4-диоксопиперидиновые соединения для их получения
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
EA200500172A1 (ru) Азабициклопроизводные в качестве антагонистов мускариновых рецепторов
PE20061318A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
MX2008011576A (es) Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.
EA200600688A1 (ru) Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а
EA200501594A1 (ru) Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
WO2004093789A3 (en) Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
WO2006114666A8 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
MXPA06000774A (es) E3-nitro-pirazolo[1,5-a]pirimidinas 7-sustituidas y composiciones y metodos relacionados.
TNSN05324A1 (en) 7-substituted 3-nitro-pyrazolo `1,5-a! pyrimidines
RO200800818A8 (ro) Compus tetrapirolic nesimetric substituit - procedeu de obţinere şi evaluare biologică la nivel celular

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed